understanding, comfort level, and moral acceptance of this practice (Dickinson, Clark, Winslow, & Marples, 2017; Harris, 2014; Stokes, 2017; Vooerhees, Rietjens, van der Heide, & Drickamer, 2014) . Many genetic counselors provide care for patients with lifethreatening illness (78%) or patients who have died (68%) (Geller et al., 2010) . However, many (29%) do not feel comfortable or adequately trained to address issues of dying and end-life care (Geller et al., 2010) . Several studies have highlighted the need for genetic counselors to be better integrated into end-of-life care and to discuss end-of-life issues earlier on in the course of disease (Knebel & Hudgings, 2002; Morrow, Jacobs, Best, Greening, & Tucker, 2017; Quillin et al., 2017; Quillin, Bodurtha, & Smith, 2008; Wool & Dudek, 2013) . Still, it is not clear how or whether genetic counseling and PAD intersect, and there are no published studies to date investigating genetic counselors' experiences with, or perspectives about, PAD. This exploratory study sought to assess genetic counselors' experiences, perspectives, role, perceived knowledge, and training related to PAD in US states where the practice is legal.
| ME THODS

| Participants and instrumentation
The study recruitment strategy was designed to identify genetic counselors who may have had PAD arise in their professional practice. Initially, genetic counselors who self-identified as working in neurology, oncology, or adult genetics were recruited by email using the National Society of Genetic Counselors (NSGC) directory from states where PAD was legal at the time (e.g., California, Colorado, Montana, Oregon, Vermont, Washington, and Washington DC). 
| Data analysis
Qualitative analysis was conducted using a deductive approach to formulate initial codes based on our research questions, literature review and interview guide (Fereday & Muir-Cochrane, 2006) . Additional codes were developed following an inductive approach, where new codes were allowed to emerge after initial review of the transcripts by team members and were added to our codebook.
Each question of the interview was structurally and thematically coded. Coding was conducted collaboratively and manually by two members of the team (AD, HKT) who had experience in qualitative analysis and thematic coding, and any discrepancies were resolved through discussion. Summaries of each code's output were created and discussed by the team to identify patterns that fit the data.
| RE SULTS
A total of 15 telephone interviews were conducted by a single interviewer (AD). Interviews ranged from 18-46 min (mean 22 min).
Almost all the participants were female (n = 14) and self-identified as white (n = 14). The majority practiced in California (n = 13), with one each from Oregon and Washington. Almost half of respondents reported that they worked within a university medical center (n = 7).
Most participants currently worked in multiple specialties, with the most common being oncology (n = 9). (Table 1) .
| Professional experiences with PAD
Five participants said they had a patient ask about PAD. For each participant, the number of patients who had asked about PAD ranged from 1-5. (Table 2 ). Of these five participants, two reported PAD coming up before, and three reported it coming up after, PAD was legalized in their state. Four of these participants practiced in California and one practiced in Oregon. Genetic counselors reported that patients raised the topic of PAD in two settings: oncology and neurology. For the three participants who had experiences in a neurology setting, the contexts in which PAD was introduced by patients were: (a) predictive genetic testing in a presently healthy person that informed them of future prognosis in a way that raised question for PAD and (b) receiving a positive predictive result that caused someone to think about PAD given their lived experience with family members affected with the same disease who they watched suffer through the end of life. For the two participants in a cancer setting, PAD was brought up by patients in the context of: (a) recurrent or metastatic disease and (b) the relevant timing of the passing of PAD laws in their state.
Some participants described feeling surprised and unprepared when a patient raised the topic of PAD in a genetic counseling session.
One participant said, "I was caught more off-guard...it's just that it kind of came out of the blue. I wasn't expecting it…I was not prepared. It caught me by surprise, her bringing that up." (Participant 13, California).
Another described similar unpreparedness in how to respond, "…I felt less comfortable knowing, if anything, what I was supposed to do in terms of supporting her or documenting this…I did not know who to contact at [center] to let them know about this, but I felt like it was not something that I could just hold and not do anything about." (Participant 3, California). The same participant described wanting to respect and support the patient in her request for information about PAD, but feeling ill-equipped to meet her informational needs:
In my mind, I wanted to help this person in a very respectful way. And in my mind, I knew I absolutely support you on this decision, but I didn't know what to do other than to say, 'you have my word and let me find resources for you'. And to also say, 'it doesn't mean you need to go through with this, but you'll have information you need to make this decision' I felt woefully ill-prepared to help her with the next step, but I felt very comfortable in hearing her talk about this and respecting her choice.
(Participant 3, California).
| PAD and the role of genetic counselors
All participants were asked what they thought the role of genetic counselors should be in discussions of PAD and why. They described four key professional skills and areas of expertise and experiences of genetic counselors that they thought were relevant to PAD discussions, and which made genetic counselors appropriate health care providers to discuss PAD with patients. First, several participants (n = 7) mentioned the nature of the empathic and trusting relationship with genetic counseling patients. This was seen as making it an appropriate context for discussion of PAD and other end-of-life issues, even if it might be more relevant at a time in the future. For some patients, getting a genetic diagnosis may result in challenging Another participant said that patients might be more comfortable talking with genetic counselors than with other providers about PAD:
Well, I think if we're doing our jobs well then we're cer- Second, participants said that genetic counselors have experience and skills in addressing challenging topics related to things like PAD and end-of-life preferences (n = 8). As one participant said, "We deal with very sensitive psychologically and emotionally sensitive topics all the time. We deal with difficult family dynamics. We deal with chronic illness. So, yeah, I think we could definitely be well-suited in this area." (Participant 10, California).
Another participant highlighted the profession's counseling and advocacy expertise: "I mean we're trained in empathy and active listening and advocating for our patient, so I honestly think that we're in one of the better positions to make that safe zone and comfort for the patient where they may feel inclined to bring this up." (Participant 8, California).
Third, participants cited the role of the genetic counselor in value-based shared decision making as being potentially useful in discussions involving PAD (n = 7). One participant made an analogy to the kind of value-based counseling involved in decisions about prenatal diagnosis, explaining:
The whole principle of nondirective counseling where I'm not trying to tell you what to do, but I want to help you make the best decision for you.
Like that's a principle we use all the time. I used it all the time in prenatal…people say, 'should I have an TA B L E 2 Participant experiences with PAD Participant 3, Cancer "Yes. This was a patient newly diagnosed with pancreas cancer who was in severe pain, and she stated multiple times that she wished to die with dignity and take advantage of the dying with dignity act. She had a past diagnosis of breast cancer when she was younger…She was in her 60's with this new diagnosis."
Participant 9, Neurology "…I've had a few Huntington's patients who wanted to have that discussion and then of course, in a way, I think about termination of pregnancy along the same spectrum.
[…] One gentleman I remember quite well…he wanted to end his life. It didn't feel really scary. It felt a lot more thought out than scary. It didn't feel like he was in danger right at that moment." Participant 12, Neurology "One [time PAD was brought up] was at a conference that was for families who had prion disease, which is like Creutzfeldt-Jakob disease. There was a gentleman who knew he had a gene and that he would eventually develop this condition, and he had researched where he could go to actually have PAD. He talked to people in Canada, people in Europe, and was sort of making a plan to move to a place where he could have access to this. For him, it was a lot about, 'I've watched my relatives go through this and have this terrible death, and I don't want that for myself. I don't want to burden other people.' So for him, it was a really strong knowledge about what the end of his life would look like and wanting to protect his family from having to go through that." "The other time I've had it happen, was with a patient who after learning her genetic status that she did have a gene that would eventually cause her to have a similar disease to her sister's kind of end stage where she was at the time."
Participant 13, Cancer "This was a woman that had been diagnosed with cancer three different times in her life and her most recent diagnosis was, unfortunately, metastatic melanoma. She just had a PET scan and got the results. So, she came in to see me and she was clearly upset. And her genetic testing from my aspect was completely negative, but what had happened was that she had been put on a new drug and the PET scan had shown the cancer was pretty much everywhere and the treatment had no impact on the tumors…Then she said, 'I'm going to talk to Dr. A' -and I think the law it had just passed but hadn't officially started, so it was right in then, and she knew it was available. So that was kind of the time frame, and she said, 'I'm thinking of this now and I'm going to talk to Dr. "A" and bring it up.' So between the results of the PET scan happening and the law passing, this was something she wanted to look into a little more."
Note. PAD: Physician aid-in-dying.
amnio or shouldn't I?' And I come back with, 'let's try to think about the best way to answer that question for you. ' Another participant who had experience discussing PAD with patients echoed this perspective:
In [sic] the people that I talked about it before, they've experienced the illness, they potentially cared for someone who had a slow and painful demise that might make people more protective of their own immediate family that would be caring for them -that they don't want them to go through that. I think someone who is having an illness they haven't had experience with before, like a brain cancer or something, they haven't cared for someone with that illness, they don't know exactly what it's going to look like. Maybe that wouldn't provoke that reaction as it would for somebody's whose lived it, or cared for a parent with Huntington's, or a parent with a dementia that was really debilitating.
(Participant 12, California).
Participants also discussed the implications of predictive genetic testing, especially when the natural history is clearly defined and there may be a poor prognosis (n = 6). One participant described PAD as related to long-term planning: "The only thing that I think could be different about genetic conditions is if there's presymptomatic testing available for the condition, so you could have even more foresight about being impacted." (Participant 7, California).
When asked directly, most participants (n = 11) said it would be appropriate for a genetic counselor to refuse to discuss PAD if they felt morally uncomfortable with the practice. These participants stipulated that this would be acceptable as long as the genetic counselor referred the patient to other providers or information resources in a nondirective and nonjudgmental way. As one participant described, "As long as they were able to respectfully refer out and say that this is not something that they typically handle. It's important that I think it's important for counselors to be able to take care of their own needs, but I also think it's important for them to figure out how to serve the patient even if they are not going to do it personally.
(Participant 1, Washington).
While participants identified key professional skills that are relevant to PAD, some (n = 5) expressed doubt that the topic of PAD would come up frequently in a genetic counseling appointment. Of these participants, most stated that other health care providers would be more useful and/or appropriate to address the issue with patients. One said, "I just don't think it happens very often. You know, if someone had lung cancer, I can see them more going to their oncologist and those kind of providers more than genetic counselors." (Participant 11, California).
Another participant said that her role would be to alert providers to discuss the topic: "Let's just say they bring it up, what would I actually do with that information? I would probably, in my chart note that will go back to the oncologist, say, 'Ms. Smith mentioned that assisted suicide is something she is considering.'…so that they would have a heads-up so when they see her the next time, that's something they would bring up with her." (Participant 13, California).
| Perceived knowledge of PAD
More than half (n = 8) of the participants acknowledged their own lack of knowledge about PAD, including one participant who discussed PAD with a patient. She said, "I know very little. I mean I know in California it has been discussed, and I knew about the Oregon law and then when it was voted upon this year -or I can't remember the exact timing of it -I haven't read the law." (Participant 13, California).
While some participants had heard about PAD in the media, few understood the laws or practical steps involved. One participant said, "I had heard about it a couple of years ago through the media. said that they felt underprepared to discuss PAD with patients for three main reasons. First, they said that they have a lack of understanding of the laws the process of PAD. One participant clearly explained, "I don't have enough information about this to have any kind of practical conversation with a patient about it."
(Participant 2, California). Several others explained that while they feel informationally ill-equipped, they would feel comfortable with the counseling, "I would feel comfortable talking about the emotional aspects of it, but I wouldn't know information about legal or logistical stuff like how a patient would actually go about doing it."
Second, some participants said that they felt unprepared because they have never had any experience discussing PAD with patients. As one genetic counselor explained: "I think because I haven't talked about it with any patient before, the first few times I wouldn't feel comfortable…so it would take some time to get some comfort level there." (Participant 5, California).
Third, several participants said that they worried about unintentionally misinforming patients about PAD because of their lack of familiarity with the practice. One participant from California said, "I think I would not want to get into a discussion where the patient was looking for information or guidance from me, and I just wasn't familiar enough with the topic to be able to give them guidance. I wouldn't want to mislead them in any way or give them the impression that I knew more than I did." (Participant 6, California). Perhaps because of the recent legalization of PAD in some states, the majority of genetic counselors in our study reported that they do not feel prepared to have these discussions and want additional training.
It is perhaps unsurprising that the scope of genetic counseling might include discussions of PAD. Patient reactions to genetic diagnoses may be compounded by prior experiences witnessing or caring for affected family members, and these individuals may have specific questions about quality of life and the dying process (Booij, Tibeen, & Engberts, 2014; Brouwer-DudokdeWit, Savenije, Zoetewij, Maat-Kievit, & Tibeen, 2002; Klitzman, 2012; Mand, Gillam, Duncan, & Delatycki, 2015) . Resta et al., 2006) . This suggests that genetic counselors should be prepared to be asked questions about PAD and refer patients to other providers for more specific guidance.
A clear parallel was observed by some participants between the role of a genetic counselor in discussing PAD in the context of a genetic diagnosis and discussing termination of pregnancy in the context of a prenatal diagnosis. A small amount of literature exists regarding how genetic counselors respond to discussions of termination of pregnancy when they feel morally uncomfortable (Allen & Mulhauser, 1995; Burke, 1992; Wool & Dudek, 2013) , as well as strategies they employ in these contexts, which include referrals to other providers and use of psychological coping mechanisms that consider nondirectiveness and their own values of autonomy (Burke, 1992) . The use of similar strategies may be effective if genetic counselors are uncomfortable with discussions of PAD and could be incorporated into PAD educational initiatives. Our participants agree with the recommendations of others that those who feel morally opposed to discussing PAD with patients should be allowed to exercise conscientious objection, as long as they can make referrals to other willing providers (Harman & Magnus, 2017) .
| Practice implications
This study provides evidence that some genetic counselors are being asked about PAD and should anticipate that it could arise in several Genetic counselors also may need to consider how discussions of PAD will intersect with other emotionally charged discussions among family members in their practice. These discussions may include divided and strong opinions around testing, reproductive decision-making, treatment, and end-of-life planning. Because PAD may be perceived by some as a highly controversial topic, genetic counselors may find that their non-directive mediation skills are useful in these conversations.
Our findings also indicate that some genetic counselors feel unprepared to answer these questions, and want and need education and training and professional guidance about what to say to patients. 
| Study limitations
The generalizability of these findings is limited by our small sample size and the fact that the majority our participants (n = 13) were from California. Our results likely overestimate knowledge, interest and experience with PAD, and have limited generalizability to other states. Despite these limitations, this study clearly demonstrates that at least some genetic counselors are being asked about PAD and that the issue is relevant and important to genetic counseling practice in some clinical settings.
| Research recommendations
More research is needed to further characterize how and whether PAD discussions are occurring across genetic counseling contexts, including larger sample sizes, more diverse specialties, and greater geographic representation. Research recording and analyzing conversations between genetic counselors and patients about PAD could provide important information to suggest best practices.
There is also a need for research to develop and test educational tools for genetic counselors about PAD.
| CON CLUS IONS
This exploratory study demonstrates that genetic counselors in states where PAD is legal have, at least sometimes, been asked by patients and families about the practice and expect to be asked in the future. Our study participants identified key professional skills and experiences within their role and scope of practice that are relevant to, and could incorporate, discussions of PAD. Participants want educational and professional guidance on how to discuss PAD with patients. As PAD becomes more widely available, more data will be needed about how genetic counselors address and incorporate the topic in their clinical practice.
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E N D N OTE S
1 At the time of recruitment and interviews for this study, the End of Life Option Act in the state of California was in effect. On May 15, 2018 a judge issued a temporary ruling suspending the law. On June 15, 2018, a court of appeals granted the state's request to reinstate the law while the court considers the case. As of the time of this manuscript submission, the law is currently in effect in California (Coalition for Compassionate Care, 2018).
2
Hawaii enacted state legislature approving Physician Aid-in-Dying in 2018 (after data collection of this study).
3 Under the law in all states in the US where PAD is legal, the patient must have capacity to make the request both orally and in writing (FindLaw, 2018) .
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